Journal article
A phase II study of ifosfamide, cisplatin, etoposide in patients with advanced non-small cell lung cancer: a preliminary report.
Abstract
Twenty previously untreated patients with histologically or cytologically proven non-small cell lung cancer (NSCLC) were treated with ifosfamide in combination with cisplatin and etoposide. Patients received ifosfamide 4 g/m2 with mesna uroprotection on day 1 and cisplatin 25 mg/m2 and etoposide 100 mg/m2 on days 1 through 3. Courses were repeated every 28 days. Premedication with prochlorperazine, dexamethasone, and high-dose metoclopramide …
Authors
Shepherd FA; Goss PE; Latreille J; Stewart D; Logan D; Evans WK; Maroun J; Warner E
Journal
Seminars in Oncology, Vol. 17, No. 2 Suppl 4, pp. 19–23
Publication Date
4 1990
ISSN
0093-7754